Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Exact Sciences (EXAS) PT Raised to $82 at BTIG
September 16, 2024 3:09 PM EDTBTIG analyst Mark Massaro raised the price target on Exact Sciences (NASDAQ: EXAS) to $82.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "Shares of EXAS are up ~5% today (and +20% in the last few days) following EXAS' blood-based CRC test readout from a ~3,000 patient, partial case control study read out during the European Society of Medical Oncology (ESMO)... More
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
September 16, 2024 8:26 AM EDTCiti analyst Patrick Donnelly reiterated a Buy rating and $80.00 price target on Exact Sciences (NASDAQ: EXAS).
The analyst comments "This morning, EXAS released initial data on their blood-based CRC test at ESMO. The test showed overall CRC sensitivity of 88.3%, specificity of 90.1%, and AA... More
